Palvella Therapeutics, Inc. Realized Investment Gains (Losses)
Palvella Therapeutics, Inc. (PVLA) reported Realized Investment Gains (Losses) of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RealizedInvestmentGainsLosses · last filed 2024-11-13
- Palvella Therapeutics, Inc. realized investment gains (losses) for the quarter ending 2024-09-30 was $0.00.
- Palvella Therapeutics, Inc. realized investment gains (losses) for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. realized investment gains (losses) for the quarter ending 2024-03-31 was $0.00.
- Palvella Therapeutics, Inc. realized investment gains (losses) for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. realized investment gains (losses) for fiscal 2023 was $53.00K, a 85.90% decline from fiscal 2022.
- Palvella Therapeutics, Inc. realized investment gains (losses) for fiscal 2022 was $376.00K.
- Palvella Therapeutics, Inc. realized investment gains (losses) for fiscal 2021 was $0.00.
- Palvella Therapeutics, Inc. realized investment gains (losses) for fiscal 2019 was $300.00K, a 70.00% decline from fiscal 2018.
| Period end | Realized Investment Gains (Losses) 3 month | Realized Investment Gains (Losses) 6 month | Realized Investment Gains (Losses) 9 month | Realized Investment Gains (Losses) 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-11-13 | $106.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $106.00K derived: sum of 3 quarters · filed 2024-11-13 | $53.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $106.00K derived: sum of 2 quarters · filed 2024-11-13 | $53.00K 10-Q · filed 2024-11-13 | $130.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $106.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $53.00K 10-Q · filed 2024-08-14 | $130.00K derived: sum of 3 quarters · filed 2024-08-14 | $469.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$53.00K 10-Q · filed 2024-05-15 | $24.00K derived: sum of 2 quarters · filed 2024-05-15 | $363.00K derived: sum of 3 quarters · filed 2024-05-15 | $323.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $416.00K derived: sum of 2 quarters · filed 2024-03-29 | $376.00K derived: sum of 3 quarters · filed 2024-03-29 | $376.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $299.00K derived: sum of 2 quarters · filed 2023-11-14 | $299.00K 10-Q · filed 2023-11-14 | $299.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$40.00K 10-Q · filed 2023-08-10 | -$40.00K derived: sum of 3 quarters · filed 2023-08-10 | -$40.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | $0.00 derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $0.00 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2019-12-31 | $300.00K 10-K · filed 2020-03-13 | |||
| 2018-12-31 | $1.00M 10-K · filed 2020-03-13 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |